Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 92 entries
Sorted by: Best Match Show Resources per page
Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters.

Translational oncology

Surov A, Gottschling S, Mawrin C, Prell J, Spielmann RP, Wienke A, Fiedler E.
PMID: 26692534
Transl Oncol. 2015 Dec;8(6):517-23. doi: 10.1016/j.tranon.2015.11.012.

OBJECTIVES: To analyze diffusion-weighted imaging (DWI) findings of meningiomas and to compare them with tumor grade, cell count, and proliferation index and to test a possibility of use of apparent diffusion coefficient (ADC) to differentiate benign from atypical/malignant tumors.METHODS:...

Cite
Surov A, Gottschling S, Mawrin C, et al. Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. Transl Oncol. 2015;8(6):517-23doi: 10.1016/j.tranon.2015.11.012.
Surov, A., Gottschling, S., Mawrin, C., Prell, J., Spielmann, R. P., Wienke, A., & Fiedler, E. (2015). Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. Translational oncology, 8(6), 517-23. https://doi.org/10.1016/j.tranon.2015.11.012
Surov, Alexey, et al. "Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters." Translational oncology vol. 8,6 (2015): 517-23. doi: https://doi.org/10.1016/j.tranon.2015.11.012
Surov A, Gottschling S, Mawrin C, Prell J, Spielmann RP, Wienke A, Fiedler E. Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. Transl Oncol. 2015 Dec;8(6):517-23. doi: 10.1016/j.tranon.2015.11.012. PMID: 26692534; PMCID: PMC4700293.
Copy Download .nbib Format: NLM
Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence.

Surgical neurology international

Landeiro JA, Fonseca EO, Monnerat AL, Taboada GF, Cabral GA, Antunes F.
PMID: 26674325
Surg Neurol Int. 2015 Nov 26;6:179. doi: 10.4103/2152-7806.170536. eCollection 2015.

BACKGROUND: We report our surgical series of 35 patients with giant nonfunctioning pituitary adenomas (GNFPA). We analyzed the rule of Ki-67 antigen expression in predicting recurrence.METHODS: Thirty-five patients were operated between 2000 and 2010. Suprassellar extension of the tumors...

Cite
Landeiro JA, Fonseca EO, Monnerat AL, et al. Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surg Neurol Int. 2015;6:179doi: 10.4103/2152-7806.170536.
Landeiro, J. A., Fonseca, E. O., Monnerat, A. L., Taboada, G. F., Cabral, G. A., & Antunes, F. (2015). Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surgical neurology international, 6179. https://doi.org/10.4103/2152-7806.170536
Landeiro, José Alberto, et al. "Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence." Surgical neurology international vol. 6 (2015): 179. doi: https://doi.org/10.4103/2152-7806.170536
Landeiro JA, Fonseca EO, Monnerat AL, Taboada GF, Cabral GA, Antunes F. Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surg Neurol Int. 2015 Nov 26;6:179. doi: 10.4103/2152-7806.170536. eCollection 2015. PMID: 26674325; PMCID: PMC4665135.
Copy Download .nbib Format: NLM
Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome.

Iranian journal of neurology

Peimani Z, Banihashemi MA, Namazi N, Safari A, Monabati A, Mojallal M, Borhani-Haghighi A.
PMID: 24800046
Iran J Neurol. 2014;13(1):40-4.

BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles. The aim of this study was to determine if pathological characteristics in non-thymomatous patients of MG would correlate with prognosis in a three...

Cite
Peimani Z, Banihashemi MA, Namazi N, et al. Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome. Iran J Neurol. 2014;13(1):40-4
Peimani, Z., Banihashemi, M. A., Namazi, N., Safari, A., Monabati, A., Mojallal, M., & Borhani-Haghighi, A. (2014). Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome. Iranian journal of neurology, 13(1), 40-4.
Peimani, Zeinab, et al. "Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome." Iranian journal of neurology vol. 13,1 (2014): 40-4.
Peimani Z, Banihashemi MA, Namazi N, Safari A, Monabati A, Mojallal M, Borhani-Haghighi A. Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome. Iran J Neurol. 2014;13(1):40-4. PMID: 24800046; PMCID: PMC3968356.
Copy Download .nbib Format: NLM
Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1.

Histopathology

McCormick D, Chong H, Hobbs C, Datta C, Hall PA.
PMID: 12405952
Histopathology. 2002 Sep;41(3):173-8. doi: 10.1046/j.1365-2559.2002.14891.x.

No abstract available.

Cite
McCormick D, Chong H, Hobbs C, et al. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology. 2002;41(3):173-8doi: 10.1046/j.1365-2559.2002.14891.x.
McCormick, D., Chong, H., Hobbs, C., Datta, C., & Hall, P. A. (2002). Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology, 41(3), 173-8. https://doi.org/10.1046/j.1365-2559.2002.14891.x
McCormick, D, et al. "Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1." Histopathology vol. 41,3 (2002): 173-8. doi: https://doi.org/10.1046/j.1365-2559.2002.14891.x
McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology. 2002 Sep;41(3):173-8. doi: 10.1046/j.1365-2559.2002.14891.x. PMID: 12405952.
Copy Download .nbib Format: NLM
Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Batistatou A, Zolota V, Tzoracoleftherakis E, Scopa CD.
PMID: 11240696
Int J Gynecol Cancer. 2000 Jul;10(4):336-339. doi: 10.1046/j.1525-1438.2000.010004336.x.

Serous adenocarcinoma of the endocervix is a rare carcinoma similar to the serous carcinoma of the ovary and the endometrium. We report a case of a 63-year-old woman with papillary serous adenocarcinoma arising within the endocervix, describing the clinical...

Cite
Batistatou A, Zolota V, Tzoracoleftherakis E, et al. Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile. Int J Gynecol Cancer. 2000;10(4):336-339doi: 10.1046/j.1525-1438.2000.010004336.x.
Batistatou, A., Zolota, V., Tzoracoleftherakis, E., & Scopa, C. D. (2000). Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 10(4), 336-339. https://doi.org/10.1046/j.1525-1438.2000.010004336.x
Batistatou, A., et al. "Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 10,4 (2000): 336-339. doi: https://doi.org/10.1046/j.1525-1438.2000.010004336.x
Batistatou A, Zolota V, Tzoracoleftherakis E, Scopa CD. Papillary serous adenocarcinoma of the endocervix: A rare neoplasm. Immunohistochemical profile. Int J Gynecol Cancer. 2000 Jul;10(4):336-339. doi: 10.1046/j.1525-1438.2000.010004336.x. PMID: 11240696.
Copy Download .nbib Format: NLM
Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Hidalgo Grau LA, Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogués JM, Sala JS.
PMID: 18333072
HPB (Oxford). 2004;6(3):174-80. doi: 10.1080/13651820410025110.

BACKGROUND: The overexpression of p53 protein and the expression of Ki-67 antigen may affect the survival of patients with gallbladder carcinoma. This association has been tested in a series of 41 patients with relatively early carcinoma of the gallbladder.METHODS:...

Cite
Hidalgo Grau LA, Badia JM, Salvador CA, et al. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford). 2004;6(3):174-80doi: 10.1080/13651820410025110.
Hidalgo Grau, L. A., Badia, J. M., Salvador, C. A., Monsó, T. S., Canaleta, J. F., Nogués, J. M., & Sala, J. S. (2004). Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB : the official journal of the International Hepato Pancreato Biliary Association, 6(3), 174-80. https://doi.org/10.1080/13651820410025110
Hidalgo Grau, Luis A, et al. "Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. 6,3 (2004): 174-80. doi: https://doi.org/10.1080/13651820410025110
Hidalgo Grau LA, Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogués JM, Sala JS. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford). 2004;6(3):174-80. doi: 10.1080/13651820410025110. PMID: 18333072; PMCID: PMC2020674.
Copy Download .nbib Format: NLM
Comparison of 4 proliferation markers and their significance for evaluation of tumor dignity in intracranial tumors.

International journal of oncology

Hagel C, Schwartz P, Laas R, Stavrou D.
PMID: 21552814
Int J Oncol. 1995 Jul;7(1):107-13. doi: 10.3892/ijo.7.1.107.

The proliferation indices of immunohistochemically detected bromodeoxyuridine, Ki-67 antigen (antibodies Ki-67 and MIB 1), and proliferating cell nuclear antigen were determined manually and with computer assisted morphometry in 38 gliomas, 29 meningeomas, 9 metastases, and 16 other tumors. Comparing...

Cite
Hagel C, Schwartz P, Laas R, et al. Comparison of 4 proliferation markers and their significance for evaluation of tumor dignity in intracranial tumors. Int J Oncol. 1995;7(1):107-13doi: 10.3892/ijo.7.1.107.
Hagel, C., Schwartz, P., Laas, R., & Stavrou, D. (1995). Comparison of 4 proliferation markers and their significance for evaluation of tumor dignity in intracranial tumors. International journal of oncology, 7(1), 107-13. https://doi.org/10.3892/ijo.7.1.107
Hagel, C, et al. "Comparison of 4 proliferation markers and their significance for evaluation of tumor dignity in intracranial tumors." International journal of oncology vol. 7,1 (1995): 107-13. doi: https://doi.org/10.3892/ijo.7.1.107
Hagel C, Schwartz P, Laas R, Stavrou D. Comparison of 4 proliferation markers and their significance for evaluation of tumor dignity in intracranial tumors. Int J Oncol. 1995 Jul;7(1):107-13. doi: 10.3892/ijo.7.1.107. PMID: 21552814.
Copy Download .nbib Format: NLM
Expression of her-2/neu oncogene in breast-cancer - correlation of quantitative immunocytochemistry and prognostic factors.

International journal of oncology

Charpin C, Devictor B, Bonnier P, Andrac L, Lavaut M, Allasia C, Piana L.
PMID: 21584622
Int J Oncol. 1992 Dec;1(7):815-23.

HER-2/neu oncogene expression by breast carcinomas (n = 208) was investigated on frozen sections using monoclonal anti-p185 HER-2/neu protein. Results were evaluated by computer-assisted image analysis and correlated with morphological prognostic factors, hormone receptor antigenic sites, Ki 67 antigen...

Cite
Charpin C, Devictor B, Bonnier P, et al. Expression of her-2/neu oncogene in breast-cancer - correlation of quantitative immunocytochemistry and prognostic factors. Int J Oncol. 1992;1(7):815-23
Charpin, C., Devictor, B., Bonnier, P., Andrac, L., Lavaut, M., Allasia, C., & Piana, L. (1992). Expression of her-2/neu oncogene in breast-cancer - correlation of quantitative immunocytochemistry and prognostic factors. International journal of oncology, 1(7), 815-23.
Charpin, C, et al. "Expression of her-2/neu oncogene in breast-cancer - correlation of quantitative immunocytochemistry and prognostic factors." International journal of oncology vol. 1,7 (1992): 815-23.
Charpin C, Devictor B, Bonnier P, Andrac L, Lavaut M, Allasia C, Piana L. Expression of her-2/neu oncogene in breast-cancer - correlation of quantitative immunocytochemistry and prognostic factors. Int J Oncol. 1992 Dec;1(7):815-23. PMID: 21584622.
Copy Download .nbib Format: NLM
High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers.

Journal of breast cancer

Mandó P, Rizzo M, de la Puente CP, Maino M, Ponce C, Pombo MT, Amat M, Costanzo MV, Nervo A, Nadal J, Fabiano V, Loza J, Loza CM, Colo F, Reinaldo C.
PMID: 28690653
J Breast Cancer. 2017 Jun;20(2):170-175. doi: 10.4048/jbc.2017.20.2.170. Epub 2017 Jun 26.

PURPOSE: Several studies have shown that estrogen receptor (ER) and progesterone receptor (PR) expression and human epidermal growth factor receptor 2 (HER2) expression may vary during tumoral progression. We aimed to describe and compare ER, PR, and HER2 expressions...

Cite
Mandó P, Rizzo M, de la Puente CP, et al. High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers. J Breast Cancer. 2017;20(2):170-175doi: 10.4048/jbc.2017.20.2.170.
Mandó, P., Rizzo, M., de la Puente, C. P., Maino, M., Ponce, C., Pombo, M. T., Amat, M., Costanzo, M. V., Nervo, A., Nadal, J., Fabiano, V., Loza, J., Loza, C. M., Colo, F., & Reinaldo, C. (2017). High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers. Journal of breast cancer, 20(2), 170-175. https://doi.org/10.4048/jbc.2017.20.2.170
Mandó, Pablo, et al. "High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers." Journal of breast cancer vol. 20,2 (2017): 170-175. doi: https://doi.org/10.4048/jbc.2017.20.2.170
Mandó P, Rizzo M, de la Puente CP, Maino M, Ponce C, Pombo MT, Amat M, Costanzo MV, Nervo A, Nadal J, Fabiano V, Loza J, Loza CM, Colo F, Reinaldo C. High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers. J Breast Cancer. 2017 Jun;20(2):170-175. doi: 10.4048/jbc.2017.20.2.170. Epub 2017 Jun 26. PMID: 28690653; PMCID: PMC5500400.
Copy Download .nbib Format: NLM
Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs.

European journal of radiology open

Incandela F, Feraco P, Putortì V, Geraci L, Salvaggio G, Sarno C, La Tona G, Lasio G, Gagliardo C.
PMID: 32695849
Eur J Radiol Open. 2020 Jun 20;7:100242. doi: 10.1016/j.ejro.2020.100242. eCollection 2020.

Pituitary carcinomas (PCa) are extremely rare, indistinguishable from pituitary adenomas on histopathological grounds and have a poor prognosis. Most PCa start as PRL or ACTH secreting tumors in males, with relapsing invasive behaviour, refractoriness to medical and radiotherapy and...

Cite
Incandela F, Feraco P, Putortì V, et al. Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs. Eur J Radiol Open. 2020;7:100242doi: 10.1016/j.ejro.2020.100242.
Incandela, F., Feraco, P., Putortì, V., Geraci, L., Salvaggio, G., Sarno, C., La Tona, G., Lasio, G., & Gagliardo, C. (2020). Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs. European journal of radiology open, 7100242. https://doi.org/10.1016/j.ejro.2020.100242
Incandela, Francesca, et al. "Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs." European journal of radiology open vol. 7 (2020): 100242. doi: https://doi.org/10.1016/j.ejro.2020.100242
Incandela F, Feraco P, Putortì V, Geraci L, Salvaggio G, Sarno C, La Tona G, Lasio G, Gagliardo C. Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs. Eur J Radiol Open. 2020 Jun 20;7:100242. doi: 10.1016/j.ejro.2020.100242. eCollection 2020. PMID: 32695849; PMCID: PMC7365899.
Copy Download .nbib Format: NLM
Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping.

Pathology, research and practice

Vieira DSC, Wopereis S, Walter LO, de Oliveira Silva L, Ribeiro AAB, Wilkens RS, Fernandes BL, Reis ML, Golfetto L, Santos-Silva MC.
PMID: 34971844
Pathol Res Pract. 2021 Dec 23;230:153750. doi: 10.1016/j.prp.2021.153750. Epub 2021 Dec 23.

The Ki-67 antigen is a nuclear protein with proven prognostic value in different neoplasms and recognizes the predictive value in breast cancer (BC). No consensus exists on the ideal cutoff point. In this study, Ki-67 expression was evaluated in...

Cite
Vieira DSC, Wopereis S, Walter LO, et al. Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping. Pathol Res Pract. 2021;230:153750doi: 10.1016/j.prp.2021.153750.
Vieira, D. S. C., Wopereis, S., Walter, L. O., de Oliveira Silva, L., Ribeiro, A. A. B., Wilkens, R. S., Fernandes, B. L., Reis, M. L., Golfetto, L., & Santos-Silva, M. C. (2021). Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping. Pathology, research and practice, 230153750. https://doi.org/10.1016/j.prp.2021.153750
Vieira, Daniella Serafin Couto, et al. "Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping." Pathology, research and practice vol. 230 (2021): 153750. doi: https://doi.org/10.1016/j.prp.2021.153750
Vieira DSC, Wopereis S, Walter LO, de Oliveira Silva L, Ribeiro AAB, Wilkens RS, Fernandes BL, Reis ML, Golfetto L, Santos-Silva MC. Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping. Pathol Res Pract. 2021 Dec 23;230:153750. doi: 10.1016/j.prp.2021.153750. Epub 2021 Dec 23. PMID: 34971844.
Copy Download .nbib Format: NLM
Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping.

Pathology, research and practice

Vieira DSC, Wopereis S, Walter LO, de Oliveira Silva L, Ribeiro AAB, Wilkens RS, Fernandes BL, Reis ML, Golfetto L, Santos-Silva MC.
PMID: 34971844
Pathol Res Pract. 2021 Dec 23;230:153750. doi: 10.1016/j.prp.2021.153750. Epub 2021 Dec 23.

The Ki-67 antigen is a nuclear protein with proven prognostic value in different neoplasms and recognizes the predictive value in breast cancer (BC). No consensus exists on the ideal cutoff point. In this study, Ki-67 expression was evaluated in...

Cite
Vieira DSC, Wopereis S, Walter LO, et al. Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping. Pathol Res Pract. 2021;230:153750doi: 10.1016/j.prp.2021.153750.
Vieira, D. S. C., Wopereis, S., Walter, L. O., de Oliveira Silva, L., Ribeiro, A. A. B., Wilkens, R. S., Fernandes, B. L., Reis, M. L., Golfetto, L., & Santos-Silva, M. C. (2021). Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping. Pathology, research and practice, 230153750. https://doi.org/10.1016/j.prp.2021.153750
Vieira, Daniella Serafin Couto, et al. "Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping." Pathology, research and practice vol. 230 (2021): 153750. doi: https://doi.org/10.1016/j.prp.2021.153750
Vieira DSC, Wopereis S, Walter LO, de Oliveira Silva L, Ribeiro AAB, Wilkens RS, Fernandes BL, Reis ML, Golfetto L, Santos-Silva MC. Analysis of Ki-67 expression in women with breast cancer: Comparative evaluation of two different methodologies by immunophenotyping. Pathol Res Pract. 2021 Dec 23;230:153750. doi: 10.1016/j.prp.2021.153750. Epub 2021 Dec 23. PMID: 34971844.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 92 entries